Merck Archives

News and Trends 22 May 2015

Genzyme joins the never-ending list of Ablynx’ partners

Genzyme is joining Ablynx’ partner list, which already includes AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Sanofi subsidiary now wants to try out the Nanobody technology of Ablynx against a target at the origin of multiple sclerosis. Genzyme wants to investigate nanobodies against a target that specifically aligns with Genzyme’s early-stage multiple […]

May 22, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 15 May 2015

European companies present their cancer treatment solutions in the USA

Each year, the American Society of Clinical Oncology gathers the cancer therapy developers during five days to present their latest results. Roche seems to be the European winner of this roundup, with amazing results of alectinib in non-small cell lung cancer (NSCLC). Roche’s investigational medicine alectinib shrank tumors in nearly half of patients suffering from this […]

May 15, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 May 2015

Ablynx gets tangled up in partnerships with Big Pharma companies

The Belgium-based company is leading more than 20 pre-clinical and clinical programmes with several partners to put the Nanobody technology on the market. Companies such as AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis are part of Ablynx’s dream team. Ablynx is a biotech company developing Nanobodies. Nanobody technology was originally developed […]

May 15, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 31 Mar 2015

Merck Serono and Intrexon, to develop CAR-T Therapy

Merck Sereno, the biopharmaceutical business of Merck, and the synthetic biology leader Intrexon announced yesterday an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. CAR-T cells are genetically engineered T-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells. When CAR-T cells bind to a target, […]

March 31, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 11 Mar 2015

First Treatment Approved under Early Access to Medicine Scheme (EAMS)

Today, it has been accepted! The first drug approved through the Early Access to Medicine Scheme (EAMS), named pembrolizumab, is an immunotherapy treatment for advanced melanoma. The treatment has been developed by Merck, known as MSD outside the United States and Canada, with early development work carried out using MRC Technology’s antibody humanization expertise. EAMS is […]

March 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Dec 2014

After Merck’s Big Deal, Pfizer Collaborates with iTeos Therapeutics for Cancer Treatments

iTeos Therapeutics SA enters in a strategic collaboration with Pfizer Inc where iTeos will license to Pfizer rights to iTeos’ pre-clinical compounds targeting the enzymes expressed in many cancers. Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates. It completes a previous deal with Merck a few weeks ago. Additionally, […]

December 11, 2014 - 2 minutesmins - By Julie Lellouche

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us